NewsRoom Articles - BioMedWire (BMW)

FridayMar 20, 2026 11:15 am

Soligenix Inc. (NASDAQ: SNGX) Strengthens Rare Disease Pipeline Program Through UK Regulatory Innovation Designation

Designations granted by leading global regulatory agencies play a critical role in advancing drug-development programs. The UK Medicines and Healthcare Products Regulatory Agency granted Promising Innovative Medicine designation to Soligenix’s SGX945 (dusquetide) for the treatment of Behçet’s disease. The recent designation in the United Kingdom builds on other regulatory recognitions previously granted to dusquetide. Regulatory recognition from international health authorities can significantly shape the trajectory of emerging therapies worldwide, particularly in rare disease development where clinical pathways are often complex and resource intensive. Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing treatments for rare diseases and unmet…

FridayMar 20, 2026 10:00 am

Oncolytic Virus Therapy is Set to Transform Cancer Care

Enormous resources are being channeled into studying different ways to support the immune system in its fight against cancer. One emerging approach is the use of oncolytic viruses. This approach seeks to leverage viruses to destroy cancer by attacking and killing its cells. The approach stems from the discovery that a number of cancers are linked to viral infections, such as HPV, which has been linked to the development of head and neck cancer, as well as cervical cancer. Liver cancer has also been linked to the hepatitis B virus. A number of vaccines have been developed to prevent some of these cancers by preventing infection by these viruses. Scientists are now looking to go a step further by…

FridayMar 20, 2026 9:45 am

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Advances PP2A Inhibition Strategy in Evolving Oncology Landscape

Recent research shows how chemotherapy and immunotherapy can complement each other when used together. Within this evolving scientific landscape, LIXTE Biotechnology is pursuing a strategy designed to improve the performance of existing cancer treatments. Inhibiting PP2A with LB-100 may increase tumor sensitivity to chemotherapy and radiation while also enhancing immune system activity against cancer cells. Experts working across oncology are exploring how different treatment approaches can work together to improve outcomes for cancer patients. One area drawing significant attention involves combining immunotherapy with chemotherapy to help the immune system better recognize and attack tumors. LIXTE Biotechnology Holdings (NASDAQ: LIXT) is…

ThursdayMar 19, 2026 10:00 am

Study Finds That Marijuana Legalization Lowers Crime Rates

David Eby, the Premier of British Columbia, has revealed that a wide range of American healthcare workers, including doctors, nurse practitioners and nurses have flocked to the Canadian province in search of employment and have secured jobs. Speaking at BC Children’s Hospital on Tuesday, the premier pointed out that the progressive social values, lifestyle and public healthcare system have been instrumental in attracting U.S.-trained medical workers to B.C. He added that the province respected science while making public health policies, has a high standard of living and respects reproductive rights. These, he said, have made the province an attractive place for healthcare workers from America. He highlighted that the…

WednesdayMar 18, 2026 11:15 am

Earth Science Tech Inc. (ETST) Builds Telehealth, Pharmacy Links in Evolving Digital Care

Patients increasingly prefer access, speed and convenience, but healthcare systems also need better coordination, safer medication workflows and clearer continuity of care. DelveInsights has projected that the global telehealth market will reach $2 trillion by 2034, driven by a digital healthcare transformation. ETST is not approaching telehealth as a standalone app or referral layer but as part of a broader operating structure that includes medication fulfillment capacity and patient-facing services. Telehealth is evolving from a simple video visit into something far more comprehensive: a connected care model that can move a patient from consultation to prescription, fulfillment and follow-up inside…

WednesdayMar 18, 2026 9:00 am

Soligenix Inc. (NASDAQ: SNGX) Advances Rare Disease Innovation Through Platform Science and Expanding Therapeutic Pipeline

High-quality development platforms and translational research frameworks have become essential tools in rare-disease biotechnology. Soligenix is leveraging its platform science to expand the therapeutic reach of its development programs and explore additional disease indications. The broader emphasis of Soligenix’s platform science approach is to maximize the scientific value of its research infrastructure. Medical progress has transformed the treatment of many common illnesses, yet thousands of rare diseases still lack effective therapies. Companies working at the intersection of biotechnology innovation and rare disease research are increasingly focused on addressing these gaps, including Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company developing and…

TuesdayMar 17, 2026 10:00 am

Mirror-Image Amino Acid Shows Promise in Starving Cancer Cells

Most existing cancer treatments not only attack cancer cells but also adversely impact healthy body cells. The resultant damage to healthy tissues usually triggers side effects that often become severe, necessitating discontinuation of therapy or making quality of life worse. Scientists have been looking for better treatments that only impact malignant cells and leave healthy cells unaffected. A new preclinical study documents one such discovery leveraging the use of a mirror-image molecule. The study, conducted by a team based at Marburg University and University of Geneva, created a molecule similar to a naturally occurring amino acid referred to as cysteine. It contains sulfur within its composition. The researchers found that some cancers have a transporter on their…

MondayMar 16, 2026 9:45 am

Investing in Innovation: Evaluating the Clinical and Commercial Potential of LB-100 and Liora’s Proton Therapy

LIXTE Biotechnology Holdings and Liora Technologies recently joined forces to soon offer a real fight against cancer. LIXTE develops LB-100, a drug that enhances the effectiveness of cancer treatments, while Liora has developed a unique cancer treatment that’s believed to be more affordable, precise, and efficient than many traditional options. Together, this pair of products have incredible clinical and commercial potential, to both help the businesses succeed, while also offering better outcomes for patients suffering from cancer. LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT), a clinical-stage pharmaceutical company, and the company’s subsidiary, Liora Technologies, both develop cancer therapies that, when combined,…

FridayMar 13, 2026 10:00 am

Microbial Ecosystems Play a Big Role in the Efficacy of Cancer Immunotherapy

Significant strides have been made in leveraging checkpoint inhibitor therapy to combat a number of cancers over the recent years. However, not all malignancies respond to these therapies, and those that do often become resistant, or are discontinued due to adverse reactions within the immune system. Now, researchers have shown that gut microbiota are one of the key factors influencing the success of immunotherapy targeting PD-L1 and PD-1 gene expression. The study was published in the journal Cancer Biology and Medicine. The research team undertook a comprehensive review focused on seeking to understand how microbial ecosystems within the gut impact how patients respond to checkpoint inhibitors targeting PD-L1 and PD-1. They analyzed clinical trials, preclinical studies and available multi-omics data to ascertain how bacterial…

FridayMar 13, 2026 9:00 am

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Expands LB 100 Development Through Strategic Academic and Pharma Partnerships

LIXTE recently expanded its ovarian clear cell cancer trial in partnership with MD Anderson and GSK The company operates at the nexus of targeted cancer biology and combination therapy innovation These partnerships help underscore LIXTE’s broader strategy: enhancing established cancer treatments through its first-in-class compound LB 100 LIXTE Biotechnology Holdings (NASDAQ: LIXT) continues to promote its lead oncology asset, LB 100, through a partnership-driven model designed to accelerate development and improve scientific validation. Recently, the company announced the expansion of its ongoing clinical collaboration with the University of Texas MD Anderson Cancer Center and GSK plc to evaluate LB 100…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Soligenix Inc. (NASDAQ: SNGX) Strengthens Rare Disease Pipeline Program Through UK Regulatory Innovation Designation

Oncolytic Virus Therapy is Set to Transform Cancer Care

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Advances PP2A Inhibition Strategy in Evolving Oncology Landscape

Study Finds That Marijuana Legalization Lowers Crime Rates

Earth Science Tech Inc. (ETST) Builds Telehealth, Pharmacy Links in Evolving Digital Care

Soligenix Inc. (NASDAQ: SNGX) Advances Rare Disease Innovation Through Platform Science and Expanding Therapeutic Pipeline

Mirror-Image Amino Acid Shows Promise in Starving Cancer Cells

Investing in Innovation: Evaluating the Clinical and Commercial Potential of LB-100 and Liora’s Proton Therapy

Microbial Ecosystems Play a Big Role in the Efficacy of Cancer Immunotherapy

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Expands LB 100 Development Through Strategic Academic and Pharma Partnerships

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search